The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DREAMM-1 Patient perspectives from the first-in-human study of single-agent belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM).
 
Laurie Eliason
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Joanna Opalinska
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline (Inst)
 
Mona L. Martin
Employment - Evidera
Research Funding - GlaxoSmithKline (Inst); Salary paid by Evidera who received research funding from GSK to conduct the study (Inst)
 
Julia Correll
Research Funding - GlaxoSmithKline
 
Benjamin Gutierrez
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Rakesh Popat
Honoraria - Celgene; GlaxoSmithKline; Janssen; Takeda
Consulting or Advisory Role - Abbvie; Celgene; GlaxoSmithKline; Takeda
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Janssen; Takeda